NASDAQ · Technology · Fiscal year endsFY ends December
DNA X Inc
SONM$2.64-0.06 (-2.22%)Today
52-week low $2.52high $11.90
77.8% below its 52-week high
Revenue by fiscal year, $ millions
-56% over the years shown (2019–2024)
Seven years, as filed
Income, cash flow and balance sheet
| $ millions | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income | |||||||
| Revenue | 116.3 | 64.0 | 54.6 | 69.8 | 93.6 | 50.9 | — |
| Revenue growth | — | -45% | -15% | +28% | +34% | -46% | — |
| Gross margin | 29.7% | 23.8% | 11.8% | 16.6% | 20.6% | 19.5% | — |
| Operating income | -22.38 | -29.26 | -38.00 | -14.29 | 0.51 | -3.10† | -5.41 |
| Operating margin | -19.3% | -45.7% | -69.6% | -20.5% | 0.5% | -6.1% | — |
| Net income | -25.83 | -29.93 | -38.63 | -14.09 | -0.09 | -33.65 | -20.66 |
| Net margin | -22.2% | -46.8% | -70.8% | -20.2% | -0.1% | -66.1% | — |
| Cash flow | |||||||
| Operating cash flow | -33.52 | -10.56 | -38.48 | -12.36 | -4.05 | -8.49 | -23.53 |
| Capital expenditure | 0.99 | 0.01 | 0.05 | 0.01 | 0.04 | 0.21 | — |
| Free cash flow (calculated) | -34.52 | -10.57 | -38.52 | -12.37 | -4.09 | -8.70 | — |
| Balance sheet | |||||||
| Cash and equivalents | 11.30 | 22.14 | 11.23 | 13.21 | 9.40 | 5.34 | 1.30 |
| Total assets | 55.46 | 50.31 | 41.09 | 53.69 | 56.04 | 39.74 | 43.90 |
| Total equity | 25.53 | 28.41 | 18.63 | 20.05 | 22.37 | -5.70 | -7.96 |
Source: DNA X Inc's 10-K and 10-Q filings, from SEC EDGAR · fiscal years end in December.
Free cash flow is calculated by The Dispatch: operating cash flow minus capital expenditure.
† Restated: a later filing changed this figure. The newer number is shown.